{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANOVA of van der Waerden scores","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.194","value":"1.09"},{"groupId":"OG001","spread":"1.899","value":"0.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"395"}],"units":"Participants"}],"description":"Total vdH-S score is sum of joint erosion score and joint-space narrowing (JSN) score. Joint erosion score summarizes erosion severity in 32 joints of hands and 12 joints of feet. Each joint scored from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Maximal erosion score is 280. JSN score summarizes severity of JSN in 30 joints of hands and 12 joints of feet. Assessment of JSN, including subluxation, is scored from 0 (normal) to 4 (bony ankylosis or complete luxation). Maximal JSN score is 168. Thus, the worst possible vdH-S score is 448.","dispersionType":"Standard Deviation","groups":[{"description":"Participants randomized to receive their stable dose of commercial MTX (between 15-25 mg/week) and placebo IV infusions at Weeks 0, 4, 12, 16, and 20. Participants will be crossed over to Golimumab 2 mg/kg at Week 24, and receive administrations at Weeks 24, 28 and q8 weeks thereafter up to Week 100. Subjects randomized to Group I (Placebo + MTX) will have the opportunity to enter early escape at Week 16 and initiate Golimumab 2 mg/kg infusions (Weeks 16, 20, and q8 weeks up to Week 100) if they demonstrate a \\< 10% improvement in both tender and swollen joint count.","id":"OG000","title":"Group I: Placebo + Methotrexate (MTX)"},{"description":"Participants randomized to receive 2 mg/kg of Golimumab intravenously at Weeks 0, 4, and q8 weeks up to Week 100. Participants will be maintained on their stable dose of commercial MTX (between 15 and 25 mg/week) throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.","id":"OG001","title":"Group II: Golimumab 2 mg/kg + Methotrexate (MTX)"}],"paramType":"MEAN","populationDescription":"Intent-to-treat: all patients analyzed according to the treatment for which they were randomized.","reportingStatus":"POSTED","timeFrame":"Week 24","title":"Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24.","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}